{
  "simulation_id": "medqa_custom_configuration_10",
  "config": {
    "use_team_leadership": false,
    "use_closed_loop_comm": false,
    "use_mutual_monitoring": true,
    "use_shared_mental_model": false,
    "use_team_orientation": false,
    "use_mutual_trust": false,
    "mutual_trust_factor": 0.8,
    "use_recruitment": true,
    "recruitment_method": "adaptive",
    "recruitment_pool": "medical",
    "random_leader": false,
    "task": "MedQA Question"
  },
  "exchanges": [
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "1_Initial Assessment Team_Internist",
      "message": "ANSWER: B  \n\n### Rationale:  \nAfter reviewing the insights from my teammates and addressing the identified issues, the most likely karyotype for this patient is **46, XY**, consistent with **Complete Androgen Insensitivity Syndrome (CAIS)**. This conclusion is supported by the patient\u2019s clinical presentation, laboratory findings, and physical examination. Below is the integrated reasoning:  \n\n---\n\n### **Clinical Presentation Supporting CAIS:**  \n1. **Primary Amenorrhea:** The patient has not had her first menstrual cycle by age 15, which is a hallmark of CAIS.  \n2. **Tanner Stage Discrepancy:** Tanner 5 breast development indicates estrogen exposure, while Tanner 2 pubic hair suggests androgen insensitivity.  \n3. **Blind Vaginal Pouch:** This finding is characteristic of CAIS, where M\u00fcllerian structures regress due to anti-M\u00fcllerian hormone (AMH) produced by the testes.  \n4. **Elevated Testosterone and Estrogen:** Elevated testosterone is produced by functional testes but cannot exert its effects due to androgen receptor dysfunction. Peripheral conversion of testosterone to estrogen explains the elevated estrogen levels and breast development.  \n5. **Elevated LH:** The lack of androgen receptor feedback leads to increased LH secretion.  \n\n---\n\n### **Systematic Analysis of Options:**  \n\n#### **A. 45, XO (Turner Syndrome)**  \n- Turner syndrome is associated with primary amenorrhea, but patients typically have short stature, streak ovaries, and lack of breast development (Tanner stage 1 or 2).  \n- The presence of Tanner 5 breast development, normal stature, and elevated testosterone and estrogen levels makes Turner syndrome unlikely.  \n- **Confidence Level: Low**  \n\n#### **B. 46, XY (Androgen Insensitivity Syndrome - AIS)**  \n- This karyotype perfectly matches the clinical findings of CAIS: primary amenorrhea, Tanner 5 breast development, sparse pubic hair, blind vaginal pouch, and elevated testosterone and estrogen levels.  \n- The mutation in the androgen receptor gene leads to androgen resistance, explaining the phenotypic female appearance despite the 46, XY karyotype.  \n- **Confidence Level: High**  \n\n#### **C. 47, XXY (Klinefelter Syndrome)**  \n- Klinefelter syndrome is seen in males with tall stature, gynecomastia, small testes, and infertility. It does not explain the patient\u2019s female phenotype, blind vaginal pouch, or hormonal profile.  \n- **Confidence Level: Very Low**  \n\n#### **D. 47, XYY**  \n- This karyotype is associated with males who are phenotypically normal and often tall. It does not explain the patient\u2019s female phenotype, Tanner stage discrepancy, or blind vaginal pouch.  \n- **Confidence Level: Very Low**  \n\n---\n\n### Addressing Teammates\u2019 Observations:  \nSeveral teammates highlighted potential contradictions in their analyses, such as mentioning Turner syndrome (45, XO) but selecting AIS (46, XY). These contradictions likely arose from considering Turner syndrome as a distant possibility due to primary amenorrhea but ultimately recognizing that the clinical findings (e.g., Tanner 5 breast development, elevated testosterone) strongly support AIS.  \n\nTo clarify, Turner syndrome (45, XO) is inconsistent with this patient\u2019s presentation, while AIS (46, XY) aligns perfectly with all clinical and laboratory findings.  \n\n---\n\n### Final Conclusion:  \nThe patient\u2019s presentation is most consistent with **Complete Androgen Insensitivity Syndrome (CAIS)**, which corresponds to a **46, XY karyotype**. This diagnosis explains the phenotypic female appearance, Tanner stage discrepancy, blind vaginal pouch, and hormonal profile.  \n\n**Final Answer:** **B**  "
    },
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "1_Initial Assessment Team_Radiologist",
      "message": "ANSWER: B  \n\n### Rationale:\nAfter integrating insights from all team members and addressing the identified issues, the most likely karyotype for this patient is **46, XY**, consistent with **Androgen Insensitivity Syndrome (AIS)**. The clinical presentation, laboratory findings, and physical exam fit the classic presentation of AIS, and this diagnosis aligns with the reasoning provided by all team members.\n\n---\n\n### Clinical Features Supporting 46, XY (AIS):\n1. **Primary Amenorrhea**: The absence of menstruation at age 15 is a hallmark of AIS.  \n2. **Breast Development (Tanner 5)**: Estrogen production from aromatization of testosterone leads to normal breast development despite androgen insensitivity.  \n3. **Sparse Pubic Hair (Tanner 2)**: Pubic and axillary hair development depend on androgen activity, which is impaired in AIS.  \n4. **Blind Vaginal Pouch**: The absence of a uterus and upper vagina is due to anti-M\u00fcllerian hormone (AMH) produced by the testes, which causes regression of M\u00fcllerian structures during fetal development.  \n5. **Elevated Testosterone, Estrogen, and LH**:  \n   - Testosterone is elevated due to functional testes, but its effects are blocked by androgen receptor insensitivity.  \n   - Estrogen is elevated due to peripheral conversion of testosterone.  \n   - LH is elevated due to lack of negative feedback from functional androgen receptors.  \n\n---\n\n### Systematic Analysis of Options:\n1. **A. 45, XO (Turner Syndrome)**:  \n   - Turner syndrome is characterized by short stature, streak ovaries, and lack of secondary sexual development (e.g., no breast development). This does not match the patient\u2019s normal stature, Tanner 5 breast development, or elevated testosterone levels.  \n   - **Confidence: Low.**\n\n2. **B. 46, XY (Androgen Insensitivity Syndrome - AIS)**:  \n   - This karyotype perfectly matches the clinical findings of AIS, including primary amenorrhea, Tanner 5 breast development, Tanner 2 pubic hair, a blind vaginal pouch, and elevated testosterone, estrogen, and LH levels.  \n   - **Confidence: High.**\n\n3. **C. 47, XXY (Klinefelter Syndrome)**:  \n   - Klinefelter syndrome typically presents in males with gynecomastia, small testes, and infertility. It does not explain the patient\u2019s female phenotype, blind vaginal pouch, or sparse pubic hair.  \n   - **Confidence: Very Low.**\n\n4. **D. 47, XYY**:  \n   - This karyotype is associated with males who are often tall and may have learning difficulties. It does not explain the patient\u2019s female phenotype or hormonal profile.  \n   - **Confidence: Very Low.**\n\n---\n\n### Addressing Team Feedback:\nThe potential contradictions in some teammates\u2019 analyses (mentioning \"A\" while selecting \"B\") were likely typographical errors. All analyses ultimately aligned with **46, XY** as the correct karyotype for this patient, based on the consistent clinical presentation of AIS.\n\n---\n\n### Final Conclusion:\nThe most likely karyotype for this patient is **46, XY**, consistent with **Androgen Insensitivity Syndrome (AIS)**. This diagnosis explains all clinical findings, including primary amenorrhea, Tanner 5 breast development, sparse pubic hair, a blind vaginal pouch, and elevated testosterone and estrogen levels.\n\n**Final Answer: B**"
    },
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "1_Initial Assessment Team_Pathologist",
      "message": "ANSWER: B  \n\n### Rationale:\nThe patient\u2019s clinical presentation, laboratory findings, and physical exam findings strongly point to **Androgen Insensitivity Syndrome (AIS)**, which is associated with a **46, XY karyotype**. This conclusion is based on the following integrated insights from all team members:\n\n---\n\n### Key Clinical Features Supporting AIS:\n1. **Primary Amenorrhea**: The absence of menstruation by age 15 in a patient with otherwise normal development is a hallmark of AIS.  \n2. **Breast Development (Tanner 5)**: Normal breast development occurs due to peripheral aromatization of testosterone to estrogen. This is typical in AIS, where the androgen receptor is nonfunctional.  \n3. **Sparse Pubic Hair (Tanner 2)**: Pubic and axillary hair growth is androgen-dependent, and its underdevelopment is consistent with androgen insensitivity.  \n4. **Blind Vaginal Pouch**: The absence of a uterus and upper vagina is characteristic of AIS, as M\u00fcllerian structures regress during fetal development due to anti-M\u00fcllerian hormone (AMH) from the testes.  \n5. **Elevated Testosterone, Estrogen, and LH**: Elevated testosterone is consistent with functional testes, but due to androgen receptor insensitivity, its effects are blocked. Testosterone is converted to estrogen, leading to feminization. Elevated LH reflects a lack of negative feedback from functional androgen receptors.  \n\n---\n\n### Systematic Analysis of Options:\n1. **A. 45, XO (Turner Syndrome)**:  \n   - Turner syndrome is associated with short stature, streak ovaries, and lack of secondary sexual characteristics. The patient\u2019s Tanner 5 breast development, normal stature, and elevated testosterone levels rule this out.  \n   - **Confidence Level: Low.**\n\n2. **B. 46, XY (Androgen Insensitivity Syndrome)**:  \n   - This karyotype is consistent with AIS. All clinical findings (primary amenorrhea, Tanner 5 breast development, sparse pubic hair, blind vaginal pouch, and elevated testosterone and estrogen) align perfectly with this diagnosis.  \n   - **Confidence Level: High.**\n\n3. **C. 47, XXY (Klinefelter Syndrome)**:  \n   - Klinefelter syndrome presents in males with gynecomastia, small testes, and infertility. It does not align with the patient\u2019s female phenotype, blind vaginal pouch, or primary amenorrhea.  \n   - **Confidence Level: Very Low.**\n\n4. **D. 47, XYY**:  \n   - This karyotype is associated with phenotypic males who may have tall stature and learning disabilities. It does not explain the patient\u2019s female phenotype or gynecologic findings.  \n   - **Confidence Level: Very Low.**\n\n---\n\n### Final Conclusion:\nThe patient\u2019s presentation is classic for **Complete Androgen Insensitivity Syndrome (CAIS)**, which corresponds to a **46, XY karyotype**. This diagnosis explains all aspects of the clinical presentation, including primary amenorrhea, Tanner 5 breast development, sparse pubic hair, blind vaginal pouch, and elevated testosterone and estrogen levels.  \n\n**Final Answer: B. 46, XY**"
    },
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "2_Domain Specialist Team_Cardiologist",
      "message": "ANSWER: B  \n\n### Rationale:  \n\nAfter integrating insights from all team members and addressing critical points, the final answer remains **B (46, XY)**. The clinical presentation of this patient strongly supports a diagnosis of **Complete Androgen Insensitivity Syndrome (CAIS)**, which is associated with a 46, XY karyotype. The rationale is as follows:  \n\n---\n\n### Clinical Features Supporting 46, XY:  \n1. **Primary Amenorrhea**: The absence of menstruation by age 15 is a hallmark of AIS, as these individuals lack a uterus due to anti-M\u00fcllerian hormone (AMH) activity during fetal development.  \n2. **Tanner Stage Discrepancy**: Tanner 5 breast development (indicative of estrogen exposure) alongside Tanner 2 pubic hair (indicative of androgen insensitivity) is characteristic of AIS.  \n3. **Blind Vaginal Pouch**: This finding is consistent with AIS, as M\u00fcllerian structures regress in individuals with a Y chromosome, leaving a shortened vagina and no uterus.  \n4. **Elevated Testosterone and Estrogen**: Elevated testosterone is produced by functional testes, but due to androgen receptor insensitivity, it is converted to estrogen, resulting in feminization.  \n5. **Elevated LH**: Elevated luteinizing hormone occurs due to the lack of negative feedback from functional androgen receptors.  \n\n---\n\n### Systematic Analysis of Options:  \n\n#### **A. 45, XO (Turner Syndrome)**  \n- Turner syndrome typically presents with short stature, streak ovaries, and lack of breast development (Tanner stage 1 or 2).  \n- The presence of Tanner 5 breast development, elevated testosterone, and normal stature in this patient makes Turner syndrome unlikely.  \n- **Confidence level: Low.**  \n\n#### **B. 46, XY (Androgen Insensitivity Syndrome - AIS)**  \n- This karyotype aligns perfectly with the clinical findings: primary amenorrhea, Tanner 5 breast development, sparse pubic hair, blind vaginal pouch, and elevated testosterone and estrogen levels.  \n- AIS occurs due to mutations in the androgen receptor, leading to resistance to androgens. This explains the phenotypically female appearance despite a 46, XY karyotype.  \n- **Confidence level: High.**  \n\n#### **C. 47, XXY (Klinefelter Syndrome)**  \n- Klinefelter syndrome is associated with phenotypic males who present with gynecomastia, tall stature, and infertility.  \n- It does not explain the patient\u2019s female phenotype, blind vaginal pouch, or Tanner stage discrepancy.  \n- **Confidence level: Very Low.**  \n\n#### **D. 47, XYY**  \n- This karyotype is associated with phenotypic males who may have tall stature and learning difficulties.  \n- It does not explain the patient\u2019s female phenotype, blind vaginal pouch, or hormonal profile.  \n- **Confidence level: Very Low.**  \n\n---\n\n### Addressing Critical Points Raised in Team Analyses:  \n\nSeveral team members mentioned potential contradictions in their reasoning, where they indicated **Option A** (45, XO) in their discussion but ultimately selected **Option B (46, XY)**. This may have stemmed from a misinterpretation of Turner syndrome or AIS features. Upon careful review of all analyses, it is clear that the clinical findings overwhelmingly support **46, XY** and not **45, XO**.  \n\nKey clarifications include:  \n- Turner syndrome (45, XO) does not explain Tanner 5 breast development or elevated testosterone levels.  \n- The presence of a blind vaginal pouch, sparse pubic hair, and elevated testosterone is classic for AIS, not Turner syndrome.  \n\n---\n\n### Final Confidence Levels:  \n1. **B (46, XY)**: 95% confidence. The clinical findings are classic for AIS.  \n2. **A (45, XO)**: 5% confidence. Turner syndrome is unlikely but was considered due to amenorrhea.  \n3. **C (47, XXY)**: <1% confidence. Klinefelter syndrome does not fit the presentation.  \n4. **D (47, XYY)**: <1% confidence. This karyotype is irrelevant to the clinical scenario.  \n\n---\n\n### Final Conclusion:  \nThe most likely karyotype for this patient is **46, XY**, consistent with **Androgen Insensitivity Syndrome (AIS)**."
    },
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "2_Domain Specialist Team_Neurologist",
      "message": "ANSWER: B  \n\n### Rationale:  \nAfter reviewing all perspectives and analyses, the most likely karyotype for this patient is **46, XY**, consistent with **Androgen Insensitivity Syndrome (AIS)**. This conclusion is supported by the clinical presentation and laboratory findings, which align perfectly with the diagnosis of complete AIS. The potential contradictions in some teammate responses (mentioning A but selecting B) do not alter the overall consensus that B is the correct answer. Below is the integrated reasoning:\n\n---\n\n### Key Clinical Features Supporting AIS:\n1. **Primary Amenorrhea:** The patient has not had her first menstrual cycle by age 15, a hallmark of disorders of sexual development like AIS.  \n2. **Tanner Stage Discrepancy:** Tanner 5 breast development indicates proper estrogenization, while Tanner 2 pubic hair suggests androgen insensitivity.  \n3. **Blind Vaginal Pouch:** This is a hallmark feature of AIS, as the M\u00fcllerian structures regress due to anti-M\u00fcllerian hormone (AMH) produced by the testes.  \n4. **Elevated Testosterone and Estrogen:** Testosterone is produced by the testes but cannot exert its effects due to androgen receptor dysfunction. It is aromatized to estrogen, leading to feminization.  \n5. **Elevated Luteinizing Hormone (LH):** LH is elevated due to the lack of negative feedback from functioning androgen receptors.  \n\n---\n\n### Systematic Analysis of Options:\n- **A. 45, XO (Turner Syndrome):**  \n   Turner syndrome typically presents with short stature, underdeveloped breasts (Tanner 1 or 2), and streak ovaries. The patient\u2019s normal stature, Tanner 5 breast development, and elevated testosterone make this karyotype unlikely.  \n\n- **B. 46, XY (AIS):**  \n   This karyotype is consistent with AIS, where androgen receptor insensitivity leads to a phenotypic female appearance despite a male genotype. The clinical findings (primary amenorrhea, Tanner 5 breast development, sparse pubic hair, blind vaginal pouch, elevated testosterone, and LH) are classic for complete AIS.  \n\n- **C. 47, XXY (Klinefelter Syndrome):**  \n   Klinefelter syndrome typically presents in males with tall stature, gynecomastia, and small testes. It does not explain the patient\u2019s female phenotype, blind vaginal pouch, or primary amenorrhea.  \n\n- **D. 47, XYY:**  \n   This karyotype is associated with males who are typically tall and may have learning difficulties. It does not explain the patient\u2019s female phenotype, blind vaginal pouch, or hormonal profile.  \n\n---\n\n### Confidence Levels:\n1. **B. 46, XY:** 95% confidence. Classic presentation of AIS.  \n2. **A. 45, XO:** 5% confidence. Inconsistent with the patient\u2019s findings but considered due to primary amenorrhea.  \n3. **C. 47, XXY:** <1% confidence. Does not align with the clinical presentation.  \n4. **D. 47, XYY:** <1% confidence. Irrelevant to the clinical scenario.  \n\n---\n\n### Final Conclusion:  \nThe patient's clinical presentation and laboratory findings are most consistent with **Androgen Insensitivity Syndrome (AIS)**, which corresponds to a **46, XY karyotype**. Therefore, the correct answer is **B**."
    },
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "2_Domain Specialist Team_Endocrinologist",
      "message": "**ANSWER: B**\n\n### Rationale:\nThe most likely karyotype for this patient is **46, XY**, consistent with **Androgen Insensitivity Syndrome (AIS)**. This conclusion is based on the integration of my expertise and the insights provided by my teammates.\n\n---\n\n### Clinical Features Supporting AIS:\n1. **Primary Amenorrhea:** The patient has not had her first menstrual cycle by age 15, which is a hallmark of AIS due to absent M\u00fcllerian structures (uterus, fallopian tubes).\n2. **Normal Breast Development (Tanner 5):** Breast development occurs because testosterone produced by the testes is converted to estrogen via aromatization. This estrogen promotes breast tissue growth, even in the absence of functional androgen receptors.\n3. **Sparse Pubic Hair (Tanner 2):** Pubic and axillary hair development depends on androgen activity, which is impaired in AIS due to androgen receptor insensitivity.\n4. **Blind Vaginal Pouch:** This is characteristic of AIS. The absence of a uterus and upper vagina occurs because anti-M\u00fcllerian hormone (AMH) produced by the testes causes regression of M\u00fcllerian structures during embryogenesis.\n5. **Elevated Testosterone and Estrogen:** Testosterone levels are elevated because the patient has functioning testes. However, due to androgen receptor insensitivity, testosterone is converted to estrogen, leading to increased estrogen levels.\n6. **Elevated Luteinizing Hormone (LH):** LH levels are elevated due to a lack of negative feedback from functional androgen receptors.\n\n---\n\n### Systematic Evaluation of Options:\n1. **A. 45, XO (Turner Syndrome):**\n   - Turner syndrome is associated with short stature, lack of breast development (Tanner 1 or 2), and streak gonads. The patient\u2019s normal stature, Tanner 5 breast development, and elevated testosterone levels make this diagnosis unlikely.\n   - **Confidence Level: Low.**\n\n2. **B. 46, XY (Androgen Insensitivity Syndrome):**\n   - This karyotype aligns perfectly with the findings. AIS explains the phenotypic female appearance, Tanner 5 breast development, sparse pubic hair, blind vaginal pouch, and elevated hormone levels. This is the most appropriate answer.\n   - **Confidence Level: High.**\n\n3. **C. 47, XXY (Klinefelter Syndrome):**\n   - Klinefelter syndrome is associated with phenotypic males who have tall stature, gynecomastia, small testes, and infertility. It does not explain the patient\u2019s female phenotype, blind vaginal pouch, or hormonal profile.\n   - **Confidence Level: Very Low.**\n\n4. **D. 47, XYY:**\n   - This karyotype is associated with phenotypic males who may have tall stature and learning difficulties. It does not explain the patient\u2019s female phenotype, blind vaginal pouch, or other clinical findings.\n   - **Confidence Level: Very Low.**\n\n---\n\n### Addressing Teammate Observations:\nSeveral teammates noted potential contradictions in their analyses, where \"A\" (45, XO) was mentioned but \"B\" (46, XY) was selected. Upon review, the correct answer remains **B (46, XY)**, as **Turner syndrome (45, XO)** does not align with the patient\u2019s clinical presentation or hormonal profile. This clarification strengthens the consensus that AIS is the correct diagnosis.\n\n---\n\n### Final Conclusion:\nThe clinical presentation is classic for **Complete Androgen Insensitivity Syndrome (CAIS)**, which is associated with a **46, XY karyotype**. All findings, including primary amenorrhea, Tanner 5 breast development, sparse pubic hair, a blind vaginal pouch, and elevated testosterone and estrogen levels, support this diagnosis. Therefore, the correct answer is **B (46, XY)**."
    },
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "3_Final Review and Decision Team_Senior Consultant",
      "message": "**ANSWER: B**\n\n### **Rationale:**\n\nAfter carefully reviewing my own analysis and integrating insights from all team members, the consensus strongly supports **46, XY** as the most likely karyotype for this patient. The clinical presentation aligns perfectly with **Complete Androgen Insensitivity Syndrome (CAIS)**, and no other karyotype explains the constellation of findings as effectively.\n\n---\n\n### **Key Clinical Features Supporting 46, XY and CAIS:**\n\n1. **Primary Amenorrhea:** The patient has not had her first menstrual cycle by age 15, which is a hallmark of CAIS.  \n2. **Normal Breast Development (Tanner 5):** This occurs due to aromatization of testosterone into estrogen. In CAIS, individuals are unable to respond to testosterone, but estrogen levels remain sufficient for breast development.  \n3. **Sparse Pubic Hair (Tanner 2):** Pubic and axillary hair development depends on androgen activity, which is impaired due to androgen receptor dysfunction.  \n4. **Blind Vaginal Pouch:** This is characteristic of CAIS, as the M\u00fcllerian structures regress during fetal development due to anti-M\u00fcllerian hormone (AMH) produced by the testes.  \n5. **Elevated Testosterone and Estrogen:** The elevated testosterone is produced by the testes but cannot exert its effects due to androgen receptor insensitivity. Peripheral conversion of testosterone to estrogen explains the elevated estrogen levels.  \n6. **Elevated LH:** The absence of negative feedback from functional androgen receptors leads to increased LH secretion.\n\n---\n\n### **Analysis of Options:**\n\n#### **A. 45, XO (Turner Syndrome):**  \n- Turner Syndrome is associated with primary amenorrhea, but these patients typically present with short stature, streak gonads, and underdeveloped breasts (Tanner stage 1 or 2).  \n- The patient\u2019s normal stature, Tanner 5 breast development, blind vaginal pouch, and elevated testosterone levels are inconsistent with Turner Syndrome.  \n- **Confidence Level: Low.**\n\n#### **B. 46, XY (Androgen Insensitivity Syndrome - AIS):**  \n- This karyotype is consistent with CAIS, where individuals are genetically male but phenotypically female due to androgen receptor insensitivity.  \n- All clinical findings (primary amenorrhea, Tanner 5 breast development, sparse pubic hair, blind vaginal pouch, elevated testosterone, estrogen, and LH) align perfectly with this diagnosis.  \n- **Confidence Level: Very High.**\n\n#### **C. 47, XXY (Klinefelter Syndrome):**  \n- This karyotype is associated with males who typically present with tall stature, gynecomastia, small testes, and infertility.  \n- Klinefelter Syndrome does not explain the patient\u2019s female phenotype, blind vaginal pouch, or hormonal profile, making it an unlikely choice.  \n- **Confidence Level: Very Low.**\n\n#### **D. 47, XYY:**  \n- This karyotype is associated with phenotypic males who may have tall stature, normal sexual development, and sometimes learning difficulties or behavioral issues.  \n- It does not explain the patient\u2019s female phenotype, blind vaginal pouch, or hormonal profile, making it the least likely option.  \n- **Confidence Level: Extremely Low.**\n\n---\n\n### **Final Conclusion:**\n\nThe most likely karyotype for this patient is **46, XY**, consistent with **Complete Androgen Insensitivity Syndrome (CAIS)**. This diagnosis explains the patient\u2019s primary amenorrhea, normal breast development, sparse pubic hair, blind vaginal pouch, and elevated testosterone and estrogen levels. All team members reached the same conclusion, and any contradictions in their analyses were likely typographical errors, as their final answers consistently supported **B**.\n\n**Final Answer:** **B**"
    },
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "3_Final Review and Decision Team_Evidence-Based Medicine Specialist",
      "message": "ANSWER: B\n\n### Rationale:\nAfter reviewing all analyses, the most consistent and logical answer is **B (46, XY)**, corresponding to **Complete Androgen Insensitivity Syndrome (CAIS)**. This integrates the insights from my teammates and addresses the clinical findings systematically. Below is the reasoning:\n\n---\n\n### Clinical Features Supporting 46, XY (CAIS):\n1. **Primary Amenorrhea**: The absence of menstruation by age 15 is a hallmark of CAIS. This is due to the absence of a uterus, caused by regression of M\u00fcllerian structures in utero (mediated by anti-M\u00fcllerian hormone from the testes).\n   \n2. **Tanner 5 Breast Development but Sparse Pubic Hair (Tanner 2)**: Breast development occurs because testosterone produced by the testes is aromatized into estrogen, which promotes breast growth. However, pubic and axillary hair development is minimal because these are androgen-dependent, and the patient\u2019s androgen receptors are nonfunctional.\n\n3. **Blind Vaginal Pouch**: This is a classic finding in CAIS. The lack of a uterus and upper vagina is due to M\u00fcllerian regression, while the presence of external female genitalia is due to androgen insensitivity.\n\n4. **Normal Stature**: The patient does not exhibit short stature or skeletal abnormalities, ruling out Turner Syndrome (45, XO).\n\n5. **Elevated Testosterone, Estrogen, and Luteinizing Hormone (LH)**: \n   - Testosterone is elevated because it is produced by the testes, but it cannot exert its effects due to androgen receptor insensitivity.\n   - Estrogen is elevated as a result of peripheral aromatization of testosterone.\n   - LH is elevated due to lack of negative feedback from functional androgen receptors.\n\n---\n\n### Systematic Analysis of Options:\n1. **A. 45, XO (Turner Syndrome)**:\n   - Turner Syndrome typically presents with short stature, streak ovaries, and lack of secondary sexual development (e.g., no breast development). The patient\u2019s normal stature, Tanner 5 breast development, and elevated testosterone make this option unlikely.\n   - **Confidence: Low.**\n\n2. **B. 46, XY (Androgen Insensitivity Syndrome)**:\n   - This is the most likely karyotype. All clinical findings\u2014primary amenorrhea, Tanner 5 breast development, sparse pubic hair, blind vaginal pouch, and elevated testosterone and LH\u2014are classic for CAIS.\n   - **Confidence: High.**\n\n3. **C. 47, XXY (Klinefelter Syndrome)**:\n   - Klinefelter Syndrome occurs in males and is associated with tall stature, gynecomastia, small testes, and infertility. It does not explain the patient\u2019s female phenotype, blind vaginal pouch, or sparse pubic hair.\n   - **Confidence: Very Low.**\n\n4. **D. 47, XYY**:\n   - This karyotype is associated with males who are typically tall and may have learning difficulties. It does not explain the patient\u2019s presentation of primary amenorrhea, female external genitalia, or blind vaginal pouch.\n   - **Confidence: Very Low.**\n\n---\n\n### Addressing Contradictions Noticed in Teammates' Analyses:\nSeveral analyses mentioned \"Option A\" in their reasoning but ultimately selected \"Option B\" as the answer. This appears to be a typographical error in their responses. However, all teammates consistently concluded that **46, XY (B)** is the correct answer based on the clinical presentation. This final answer aligns with their conclusions.\n\n---\n\n### Final Conclusion:\nThe patient\u2019s clinical findings are most consistent with **Complete Androgen Insensitivity Syndrome (CAIS)**, which is associated with a **46, XY karyotype**. This explains the primary amenorrhea, Tanner stage discrepancy, blind vaginal pouch, and hormonal profile.\n\n**Final Answer: B (46, XY)**"
    },
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "3_Final Review and Decision Team_Clinical Decision Maker",
      "message": "**ANSWER: B**\n\n### Rationale:\nAfter carefully reviewing all perspectives, including my own analysis and the insights provided by my teammates, the most consistent and evidence-based conclusion is that the patient has **Androgen Insensitivity Syndrome (AIS)**, which is associated with a **46, XY karyotype**. The clinical presentation aligns perfectly with this diagnosis.\n\n---\n\n### Integration of Insights:\n1. **Clinical Features Supporting AIS (46, XY):**\n   - **Primary Amenorrhea:** The absence of menstruation by age 15, despite normal breast development, is a hallmark of AIS.\n   - **Normal Breast Development (Tanner 5):** This is due to estrogen production via aromatization of testosterone, which occurs despite androgen receptor insensitivity.\n   - **Sparse Pubic Hair (Tanner 2):** Pubic and axillary hair are androgen-dependent, and androgen insensitivity results in underdevelopment of these secondary sexual characteristics.\n   - **Blind Vaginal Pouch:** This is a classic finding in AIS, as the absence of a uterus and upper vagina results from regression of M\u00fcllerian structures during embryogenesis due to anti-M\u00fcllerian hormone (AMH).\n   - **Elevated Testosterone and Estrogen:** Testosterone is produced by functional testes, but its effects are blocked by androgen receptor insensitivity. Aromatization of testosterone to estrogen explains the elevated estrogen levels.\n   - **Elevated LH:** The lack of feedback inhibition from functional androgen receptors leads to elevated luteinizing hormone levels.\n\n2. **Systematic Analysis of the Options:**\n   - **A. 45, XO (Turner Syndrome):**\n     - Turner syndrome is associated with short stature, lack of secondary sexual development (e.g., Tanner stage 1 or 2 breast development), and streak gonads. This is inconsistent with the patient\u2019s Tanner 5 breast development, normal stature, and elevated testosterone and estrogen levels.\n     - **Confidence: Low.**\n   - **B. 46, XY (Correct Answer):**\n     - This karyotype is entirely consistent with complete AIS, explaining all clinical findings, including primary amenorrhea, Tanner 5 breast development, sparse pubic hair, blind vaginal pouch, and elevated testosterone and estrogen levels.\n     - **Confidence: Very High.**\n   - **C. 47, XXY (Klinefelter Syndrome):**\n     - Klinefelter syndrome typically presents in phenotypic males with tall stature, gynecomastia, small testes, and infertility. It does not explain the patient\u2019s female phenotype, blind vaginal pouch, or hormonal profile.\n     - **Confidence: Very Low.**\n   - **D. 47, XYY:**\n     - This karyotype is associated with phenotypic males who may have tall stature and subtle learning difficulties. It does not explain the patient\u2019s female phenotype, blind vaginal pouch, or primary amenorrhea.\n     - **Confidence: Very Low.**\n\n3. **Addressing Contradictions in Team Analyses:**\n   - While it appears there were some formatting inconsistencies in teammate responses (e.g., mentioning \"A\" while selecting \"B\"), all analyses ultimately align in identifying **46, XY** as the correct karyotype. This reinforces the confidence in **Option B** as the final answer.\n\n---\n\n### Final Conclusion:\nThe patient\u2019s clinical presentation and laboratory findings are classic for **Complete Androgen Insensitivity Syndrome (CAIS)**, which corresponds to a **46, XY karyotype**. This diagnosis explains all observed features, including primary amenorrhea, normal breast development, sparse pubic hair, a blind vaginal pouch, and elevated testosterone and estrogen levels.\n\n**Final Answer: B. 46, XY**"
    }
  ],
  "decision_results": {
    "majority_voting": {
      "method": "majority_voting",
      "winning_option": "B",
      "vote_counts": {
        "B": 3
      },
      "total_votes": 3,
      "confidence": 1.0
    },
    "weighted_voting": {
      "method": "weighted_voting",
      "winning_option": "B",
      "vote_counts": {
        "B": 3
      },
      "weighted_votes": {
        "B": 0.78
      },
      "agent_weights": {
        "3_Final Review and Decision Team_Senior Consultant": 0.26,
        "3_Final Review and Decision Team_Evidence-Based Medicine Specialist": 0.26,
        "3_Final Review and Decision Team_Clinical Decision Maker": 0.26
      },
      "total_weight": 0.78,
      "confidence": 1.0
    },
    "borda_count": {
      "method": "borda_count",
      "winning_option": "B",
      "borda_scores": {
        "A": 0,
        "B": 9,
        "C": 0,
        "D": 0
      },
      "total_possible_score": 9.0,
      "confidence": 1.0
    },
    "mdt_process": {
      "team_decisions": {
        "1_Initial Assessment Team": {
          "method": "majority_voting",
          "winning_option": "B",
          "vote_counts": {
            "B": 3
          },
          "total_votes": 3,
          "confidence": 1.0
        },
        "2_Domain Specialist Team": {
          "method": "majority_voting",
          "winning_option": "B",
          "vote_counts": {
            "B": 3
          },
          "total_votes": 3,
          "confidence": 1.0
        },
        "3_Final Review and Decision Team": {
          "method": "majority_voting",
          "winning_option": "B",
          "vote_counts": {
            "B": 3
          },
          "total_votes": 3,
          "confidence": 1.0
        }
      },
      "decision_team": "3_Final Review and Decision Team"
    }
  },
  "teamwork_metrics": {
    "mutual_monitoring": {
      "total_monitoring_exchanges": 56,
      "total_issues_detected": 56,
      "avg_issues_per_exchange": 1.0,
      "issue_types": {
        "contradictory_selection": 56
      },
      "issue_resolution_rate": 0.0,
      "team_monitoring_effectiveness": "low"
    }
  },
  "recruitment_metrics": {
    "complexity_distribution": {
      "basic": 1,
      "intermediate": 18,
      "advanced": 3
    },
    "total_questions": 22,
    "method": "adaptive",
    "pool": "medical"
  }
}